HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Perrigo Strengthens In Europe With Sanofi Skin-Care Brands

Executive Summary

Perrigo is investing to grow its reinvigorated International consumer health business by acquiring three OTC skin-care brands from Sanofi. 

You may also be interested in...



Perrigo Exploring The CBD Opportunity

Perrigo doesn't want to miss out on the opportunity presented by CBD to offer consumers a new type of self-care product, according to the firm’s managing director, UK & Ireland, and International vice president, Neil Lister.

Ranir Oral Care Deal Could Brighten Perrigo's Turnaround Chances

Ranir has a portfolio of more than 300 oral care solutions including power toothbrushes and heads, whitening strips, manual toothbrushes, floss, dentures and travel kits that it provides to retailers and other distributors in more than 50 countries. Adding Ranir, says Perrigo CEO Murray Kessler, "illustrates a key component of our new strategy, accelerating growth by pursuing adjacent self-care categories."

Perrigo Lights Smoking Cessation For Growth With Turnaround Woes 'Fixable'

As "market leader" in OTC nicotine replacement treatments, Perrigo should "be the one that's doing a lot of innovation," says CEO Murray Kessler. He discussed Perrigo's problems and potential sales drivers as it reported 2018 net sales of $4.7bn, down 4% , and Q4 net sales of $1.2bn, down 7%. Global consumer health product sales for year were flat at $3.9bn and Q4 sales were down 4% at $973m.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1122620

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel